INTRODUCTION AND OBJECTIVES: Prescription opioids are a mainstay of postoperative pain management. We outlined the course and severity of postoperative pain in patients undergoing urethroplasty and inflatable penile prosthesis (IPP) in order to improve patient counseling and medication stewardship moving forward.
METHODS: This IRB approved, prospective study was completed between 2017 to 2018 across two institutions. All patients who underwent urethroplasty or IPP placement were invited to participate. Patients did not receive any preprocedural pain management. Patients with chronic pain or active narcotic usage were excluded. The study consisted of completing a patient-reported questionnaire which monitored end of day pain on a 1-10 visual analog scale (VAS), pain medication usage (acetaminophen, ibuprofen, and oxycodone 5 mg), and bladder spasms until initial post-operative visit 2-3 weeks after surgery. VAS was categorized into severe (10-7), moderate (6-4) and mild (3-1). Post-operative pain was similar between the two operations and was therefore evaluated together.
RESULTS: Fifteen patients (9 urethroplasty, 6 IPP) appropriately completed and returned the questionnaire. 13 patients (87%) reported mild or undetectable pain at follow up, while 2 patients had persistent pain. These groups were evaluated separately. Of the 13 patients who reported mild or resolved pain, they were only in severe pain for mean 1.4 days, with only 3 (23%) reporting any days in severe pain. Patients had their pain reduced to a mild level by a mean of 5.9 postoperative days. 9/13 (69%) patients used narcotics for a mean 3.9 days. Only 5 (38%) patients used narcotics for more than 1 day, 13 (87%) patients had leftover medication, and only 1 patient required a refill for narcotics. Patients used acetaminophen for a mean of 10.1 days and ibuprofen for 6.3 days. Only 1/9 urethroplasty patients in this group had bladder spasms. In the 2 patients whose pain persisted, they spent an average of 4.5 days in severe pain, 10.5 days in moderate pain, and 3 days in mild pain. They took narcotics, acetaminophen, and ibuprofen for a mean of 12.5, 13, and 9 days, respectively. Despite having extended pain, neither of these patients required a refill or used all prescribed narcotic. CONCLUSIONS: Most patients reported an improvement to mild pain by 6 days and used narcotics for less than 4 days after urethroplasty and IPP. The results from this study have improved our pre-operative patient counseling and helped to decrease the strength and quantity of pain medication prescribed after surgery, thereby limiting exposure to potentially dangerous narcotics.
Source of Funding: None

MP04-12 PATIENT REPORTED OUTCOMES FROM A 6 YEAR PROSPECTIVE STUDY ON SATISFACTION FOLLOWING PENILE CURVATURE SURGERY
Deji Akiboye*, London, United Kingdom; Pareeta Patel, Angus Campbell, Professor Nick Watkin, Surrey, United Kingdom INTRODUCTION AND OBJECTIVES: Subjective measures of successful penile curvature surgery are poorly defined. This study follows the 6 year development of a PROM for patients with stable Peyronie's disease (PD) undergoing corrective surgery in a single centre, measuring pre and post operative outcomes prospectively.
METHODS: Semi-structured interviews with PD patients identified four domains for assessment -penile appearance (PA), erectile function (EF), sexual relationships and generic quality of life (GQoL). A RAND consensus group of UK andrologists defined the initial itemspecific PROM 1. Questions about PA were created de-novo. EF and QoL questions were modified for PD based on IIEF and EQ5-D questionnaires respectively. PROM 1 was piloted on all patients being considered for PD surgery at a single centre over a 3 year period. A test-retest design was used for pre operative assessment, with further post operative assessment at follow up. Following statistical assessment for validity, and modification based on patient feedback, a second iteration PROM 2 was created and tested over a further 3 year period. Wilcoxon Signed Rank test was used to assess consistency between test/retest scores, and significant differences between pre and post operative scores.
RESULTS: The baseline PROM 2 was completed at first assessment by 58 men who all underwent surgery. Retest questionnaires were completed on the day of surgery with post operative questionnaires completed at first follow up. All questions had response rates >85%. Median age was 56 years (26-70 years), median time between test and retest PROMs was 169 days (13-492 days) with median time to follow up 110 days (61-299 days).
Wilcoxon Signed Rank test indicated no significant difference between pre-operative test and retest scores for PA, erectile function, relationship or GQoL (P>0.101). However, pain scores significantly reduced between test and retest assessment (P [ 0.05).
No significant difference was seen between pre and post operative EF, use of PDE5 inhibitors, penile pain, relationship or GQoL scores. Sexual relationships (P [ 0.049) and PA showed significant improvement between pre and post operative scores over all questions (P <0.001).
CONCLUSIONS: ED, use of PDE5 inhibitors and QoL are not affected by penile curvature surgery. Subjective penile appearance and sexual relationships improve significantly post operatively. There was a significant reduction in pain sensation pre-operatively and surgery did not adversely affect pain afterwards. The final iteration, PROM 3 is now suitable for internal use and external validation.
Source of Funding: None. These individuals may choose to be treated with a combination of estrogen and anti-androgen to better align their physical appearance with their gender identity. Existing literature reports variable rates of spermatogenesis in pathology specimens, limiting accurate counseling of transgender women about their fertility potential. Therefore, our goal was to evaluate spermatogenesis in pathologic specimens from transgender women on gender-affirming hormone therapy at the time of bilateral simple orchiectomy.
MP04-13 SPERMATOGENESIS IN THE TRANSGENDER TESTIS
METHODS: Following IRB approval, transgender women who underwent gender-confirming orchiectomy from 2011-2018 were identified in the Department of Pathology archives. A retrospective medical records review was performed to gather clinical information. Pathology reports were reviewed for specimen weight, dimensions of testes and description of spermatogenesis. To compare continuous variables, Students t-test was used.
RESULTS: 52 transgender women who underwent bilateral simple orchiectomy were identified (mean age 38 years, SD 13, range 22-66). All were socially transitioned (living as women); 40 of 52 (77%) were listed as female gender in the medical record and patients were on gender-affirming hormone therapy for a mean of 2.4 years (SD 2, range 1-10). Intact spermatogenesis was reported in 13.5%, hypospermatogenesis in 23.1%, no spermatogenesis in 51.9% and spermatogenesis was not reported in 11.5% of testis specimens. There was no difference in estimated testis volume among testes found to have some spermatogenesis (mean 30 cc, SD 15) versus no spermatogenesis (mean 22 cc, SD 7, p [ .10).
CONCLUSIONS: While a substantial proportion of transgender individuals do desire future fertility, historically, the reproductive needs of these patients have been largely ignored. Our study demonstrates that in testis tissue from transgender women on gender affirming hormone therapy, some (23.1%) or intact spermatogenesis (13.5%) is present at the time of bilateral simple orchiectomy. This finding has important implications for counseling transgender women about their reproductive potential.
Source of Funding: None
MP04-14 TOTAL PHALLIC RECONSTRUCTION IN THE GENETIC MALE: A SINGLE CENTRE ANALYSIS
David J Ralph*, London, United Kingdom; Marco Falcone, Mattia Anfosso, Paolo Gontero, Turin, Italy; Andrew Nim Christopher, Oliver Ralph, London, United Kingdom INTRODUCTION AND OBJECTIVES: The aim of our study is to assess surgical and patient's reported outcomes (PRO's) after a TPR using a radial artery-based forearm free flap (RAFFF).
METHODS: From September 2001 to August 2018 a consecutive series of 108 genetic male patients underwent a TPR using a RAFFF in a single tertiary referral centre secondary to a penile inadequacy. The TPR was conducted as a multiple staged procedure 1) TPR with RAFFF 2) glans sculpting 3) penile prosthesis implantation. A urethroplasty was performed in one or two stages depending on the quality of the previously reconstructive native urethra. A urethroplasty was performed in all patients even if they had had a urinary diversion (n[32) so as to enable ejaculation. The data was retrospectively extrapolated from the clinical records.
The patient's baseline features and the incidence of postoperative complications are reported. PRO's were assessed through a 4-items "ad hoc" created questionnaire and a 5-point Likert item administered through a telephone interview.
RESULTS: The aetiologies underlying the penile inadequacy were penile cancer (26%), bladder exstrophy and epispadias complex (30%), micropenis (26%) and traumatic amputation (18%). The median age at the time of the TPR was 32.5 years (IQR 24-46) and median follow-up was 78.5 mths . A primary anastamotic urethroplasty was performed in 87 patients (80.6%) and a staged urethroplasty in the remainder. A total of 77 patients (71%) completed all stages of the reconstruction including an inflatable penile prosthesis implantation.
